Name in the Protocol Name in the Model Code Description
Age age Age in years at end of patient identification period.
Inpatient Hospitalizations inpatient_hospitaliza~s Number of inpatient hospitalizations (including ER visits that lead to a hospitalization); no inpatient hospitalization is coded as ‘0’ LOS among patients with >1 asthma-related hospitalization; aggregated over period of interest (days), mean (SE), median.
ER Visits er_visits Number of ER visits; no ER visit is coded as ‘0’.
Primary Care Physician (PCP) [Family Medicine/Practice, Internal Medicine, Gerontologist] Office Visits pcp_officevisits Number of Primary Care Physician (PCP) [Family Medicine/Practice, Internal Medicine, Gerontologist] office visits; no visit is coded as ‘0’.
Specialist (Allergy/Immunology, Pulmonology, Respiratory) Office Visits specialist_office_vis~s Number of Specialist (Allergy/Immunology, Pulmonology, Respiratory) office visits; no visit is coded as ‘0’.
Other Outpatient Services other_outpatientservi~s Number of other outpatient services (eg, durable medical equipment, imaging, medication and related services, procedures, physical therapy/occupational therapy/speech, physician other services, lab tests, other); no other outpatient services is coded as ‘0’.
Asthma-Related Pharmacy Dispensing pharmacy_fills Asthma-related pharmacy dispensing (n[%] of patients with ≥1 prescription fill for all medications listed in Supplementary Material, Table S2; mean [SE]/median of fills among all patients) (refer to Supplementary Material, Table S2 for codes).
Medical Possession Ratio (MPR) mpr Medical possession ratio (MPR) for ICS, LABA, and ICS/LABA combo medications (n[%] of patients with ≥1 prescription fill; mean [SE]/median of fills among all patients) (refer to Supplementary Material, Table S2 for codes). MPR is defined as total number of treated days in the specified time period divided by total number of days from first treated day until the last treated day (including the last Rx day supply). MPR is only calculated among patients that have two or more fills with the specified medications over the specified period; MPR of patients with only one fill with the specified medications is coded as ‘0’.
Proportion of Days Covered (PDC) pdc Proportion of days covered (PDC) for ICS, LABA, and ICS/LABA combo medications (n[%] of patients with ≥1 prescription fill; mean [SE]/median of fills among all patients) (refer to Supplementary Materail, Table S2 for codes). PDC is defined as total number of treated days in the specified time period divided by total number of days from first treated day until the end of the period. Calculated only among those patients who received one or more of the specified medication(s) over the specified period.
Quan-Charlson Comorbidity Index (QCI) score qci_score Quan-Charlson comorbidity index (QCI) score; n of patients; mean (SE), median (refer to Supplementary Material, Table S3 for codes) To quantify comorbidity, the QCI score is computed by adding the weights that are assigned to the specific diagnoses. A score of 1 is attributed to myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue/rheumatologic disease, peptic ulcer disease, mild liver disease, and diabetes without chronic complications. The following diseases are scored as 2: hemiplegia or paraplegia, renal disease, diabetes with complications, and malignancy including leukemia and lymphoma. Moderate or severe liver disease is scored 3. Finally, a score of 6 is assigned to metastatic solid carcinoma and AIDS/HIV. Each diagnosis is only counted once (eg, if a patient has ICD-9 code 410.xx and 412.xx, they will receive a score of 1 for MI, not 2). The minimum possible score is 0 and the maximum possible score is 33.